On the other hand, Hastings’ study examined the molecular and clinical features of 171 EGFR mutant lung cancer cases treated with anti-PD-(L)1 alone or in combination with anti-CTLA-4 and found that outcomes were worse in patients with EGFR 19del but similar for EGFR L858R compared with EGFR wild-type NSCLC. Here, CTLA4 is linked to non-small cell lung carcinoma.